FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody CocktailBenzinga • 06/04/21
FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19PRNewsWire • 06/04/21
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Annual Bernstein Strategic Decisions Conference (Transcript)Seeking Alpha • 06/02/21
U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatmentMarket Watch • 05/28/21
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer SettingsBenzinga • 05/24/21
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced CancersPRNewsWire • 05/24/21
Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM CompetitionPRNewsWire • 05/21/21
Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse CancersPRNewsWire • 05/19/21
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at RBC Capital Markets Virtual Global Healthcare Conference Call - (Transcript)Seeking Alpha • 05/18/21
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 PatientsPRNewsWire • 05/17/21
Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in ChildrenPRNewsWire • 05/17/21
Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual PlenaryPRNewsWire • 05/12/21